Gama interferon
Reading File
Searching for comprehensive information on gamma interferon (IFN-γ).
search_medical_text
gamma interferon IFN-gamma structure function immune system
Immunotherapy for the Treatment of Hematologic Malignancies: Multiple Myeloma, Lymphoma, and Acute Leukemia
Page 10
search_medical_text
interferon gamma clinical applications tuberculosis diagnosis disease
Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
Page 507
GradeResponse
GradeResponse
The retrieved documents are relevant but limited. I'll synthesize a comprehensive answer drawing on both the retrieved content and established medical knowledge.
Interferon-Gamma (IFN-γ)
Overview
Interferon-gamma (IFN-γ), also called Type II interferon or immune interferon, is a cytokine that plays a central role in innate and adaptive immunity. Unlike the Type I interferons (IFN-α, IFN-β), which are primarily antiviral, IFN-γ is the principal immunomodulatory and macrophage-activating cytokine of the immune system.
Structure & Source
| Feature | Details |
|---|---|
| Gene locus | Chromosome 12q24.1 |
| Molecular weight | ~17 kDa (monomer); biologically active as a homodimer |
| Primary producers | CD4⁺ T helper 1 (Th1) cells, CD8⁺ cytotoxic T cells, NK cells, NKT cells |
| Receptor | IFN-γR1/IFN-γR2 heterodimer (expressed on nearly all nucleated cells) |
| Signaling pathway | JAK1/JAK2 → STAT1 → GAS elements (γ-activated sequences) |
Key Biological Functions
1. Macrophage Activation
- IFN-γ is the most potent known activator of macrophages
- Upregulates MHC class I and class II expression, enhancing antigen presentation
- Promotes oxidative burst (reactive oxygen/nitrogen species) → intracellular pathogen killing
2. Th1 Immune Polarization
- Drives CD4⁺ naive T cells toward the Th1 phenotype
- Inhibits Th2 and Th17 differentiation
- Creates a positive feedback loop: Th1 cells produce more IFN-γ
3. Antiviral & Antitumor Effects
- Upregulates antigen-processing machinery (TAP, proteasome subunits)
- Increases NK cell cytotoxicity
- Induces apoptosis in tumor cells; promotes tumor immunosurveillance
4. Antimicrobial Defense
- Critical for defense against intracellular pathogens: Mycobacterium tuberculosis, Listeria, Toxoplasma, Leishmania, Salmonella
- Triggers IDO (indoleamine 2,3-dioxygenase) — depletes tryptophan, starving intracellular pathogens
Clinical Significance
Deficiency States
| Condition | Consequence |
|---|---|
| IL-12/IL-12R deficiency | Impaired IFN-γ production → disseminated NTM/Salmonella infections |
| IFN-γR1/R2 mutations | Mendelian susceptibility to mycobacterial disease (MSMD) |
| STAT1 mutations | Recurrent mycobacterial and fungal infections |
IFN-γ Release Assays (IGRAs)
A major clinical application of IFN-γ biology is in tuberculosis (TB) diagnosis. IGRAs measure IFN-γ released by sensitized T cells in response to M. tuberculosis-specific antigens (ESAT-6, CFP-10):
- QuantiFERON-TB Gold Plus (QFT-Plus)
- T-SPOT.TB
Advantages over tuberculin skin test (TST):
- Not affected by prior BCG vaccination
- Higher specificity for M. tuberculosis (vs. NTM cross-reactivity with TST)
- Single visit required
Limitations (per Prevention and Treatment of Opportunistic Infections in HIV, p. 507):
- Indeterminate results more common in HIV-infected individuals (CD4 < 200 cells/µL)
- False-positive QFT results possible; repeat testing recommended in low-risk populations
- Sensitivity reduced in immunocompromised hosts
CDC/NTCA Guidance: IGRAs are preferred over TST in BCG-vaccinated individuals and for healthcare worker screening (2019 NTCA/CDC recommendations).
Therapeutic Applications
| Use | Agent / Context |
|---|---|
| Chronic granulomatous disease (CGD) | Recombinant IFN-γ1b (Actimmune) — FDA-approved to reduce serious infections |
| Osteopetrosis | IFN-γ1b — delays disease progression |
| Malignant melanoma / RCC | Investigated; limited clinical benefit as monotherapy |
| Anti-inflammatory balance | Excess IFN-γ contributes to hemophagocytic lymphohistiocytosis (HLH), cytokine storm — anti-IFN-γ (emapalumab) approved for primary HLH |
IFN-γ in Pathology
- Autoimmunity: Elevated in rheumatoid arthritis, SLE, psoriasis, inflammatory bowel disease
- HLH / MAS: Markedly elevated IFN-γ drives macrophage over-activation and cytopenias; emapalumab (anti-IFN-γ monoclonal antibody) is approved for refractory primary HLH
- Graft-vs-Host Disease (GvHD): IFN-γ participates in tissue damage in acute GvHD
- COVID-19: Part of the cytokine storm signature in severe disease
Summary
IFN-γ is the archetypal Type II interferon with irreplaceable roles in:
- Macrophage activation and intracellular pathogen clearance
- Th1 immune polarization
- Antigen presentation (MHC II upregulation)
- Clinical diagnostics (IGRAs for TB screening)
- Therapeutic targeting — both as a recombinant therapy (CGD) and as a target for inhibition (HLH)
This is a shared conversation. Sign in to Orris to start your own chat.